SELLAS Life Sciences Group (SLS) to Release Earnings on Thursday

SELLAS Life Sciences Group (NASDAQ:SLS) will likely be issuing its Q4 2025 results before the market opens on Thursday, March 19th. Analysts expect the company to announce earnings of ($0.0633) per share for the quarter. Individuals can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Wednesday, March 25, 2026 at 4:00 PM ET.

SELLAS Life Sciences Group Trading Down 6.0%

SELLAS Life Sciences Group stock opened at $5.04 on Wednesday. The firm has a market cap of $717.90 million, a PE ratio of -18.00 and a beta of 2.18. SELLAS Life Sciences Group has a 12 month low of $0.95 and a 12 month high of $6.14. The stock’s 50 day simple moving average is $4.38 and its two-hundred day simple moving average is $2.84.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a report on Thursday, January 22nd. Maxim Group upped their price objective on shares of SELLAS Life Sciences Group from $7.00 to $10.00 and gave the stock a “buy” rating in a research report on Thursday, March 12th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $10.00.

Hedge Funds Weigh In On SELLAS Life Sciences Group

A number of hedge funds have recently made changes to their positions in SLS. Geode Capital Management LLC raised its holdings in shares of SELLAS Life Sciences Group by 168.2% in the 2nd quarter. Geode Capital Management LLC now owns 2,200,428 shares of the company’s stock valued at $4,819,000 after buying an additional 1,379,988 shares during the period. JPMorgan Chase & Co. acquired a new position in SELLAS Life Sciences Group in the 2nd quarter valued at about $136,000. Rhumbline Advisers purchased a new stake in SELLAS Life Sciences Group during the second quarter worth about $297,000. XTX Topco Ltd purchased a new stake in SELLAS Life Sciences Group during the second quarter worth about $168,000. Finally, New York State Common Retirement Fund acquired a new stake in shares of SELLAS Life Sciences Group during the second quarter worth about $108,000. Hedge funds and other institutional investors own 17.38% of the company’s stock.

About SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.